Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.64 |
| ▸ | TPMT | P51580 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 4/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907068 | 0.87 | KMT2A (0.59) | THRBTPMTTSHRNCOA1NCOA3 | |
| SCHEMBL1457751 | 0.84 | THRB (0.48) | THRBTPMTTSHRHSD17B10NCOA1 | |
| SCHEMBL9623646 | 0.84 | TPMT (0.55) | THRBTPMTTHRATTRKMT2A | |
| SCHEMBL14907059 | 0.83 | NCOA1 (0.76) | TPMTTSHRHSD17B10NCOA1NCOA3 | |
| SCHEMBL1457769 | 0.81 | PLAU (0.64) | TPMTHSD17B10TTRKMT2AMEN1 | |
| SCHEMBL1459236 | 0.81 | MEN1 (0.65) | HSD17B10KMT2AMEN1LMNAPOLB | |
| SCHEMBL1457994 | 0.80 | MEN1 (0.57) | THRBKMT2AMEN1LMNAPOLB | |
| SCHEMBL504156 | 0.78 | TSHR (0.70) | TSHRKMT2AMEN1LMNAPOLB | |
| SCHEMBL15524451 | 0.78 | TPMT (0.59) | THRBTPMTTSHRHSD17B10LMNA | |
| SCHEMBL3546802 | 0.78 | TPMT (0.79) | THRBTPMTTSHRHSD17B10NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2473479-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | King's College London (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | THRB 642/4885TPMT 2218/4885TSHR 704/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | THRB 642/4885TPMT 2218/4885TSHR 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.